Expanding the phenotype of EP300-related Rubinstein-Taybi syndrome: Evans syndrome and DNA methylation profiling in three individuals

Abstract Background Rubinstein-Taybi syndrome type 2 (RTS2) is a rare chromatinopathy caused by pathogenic variants in EP300 and is characterised by developmental delay, distinctive facial dysmorphic features, and broad extremities. Chromatinopathies are increasingly recognised as syndromic primary immune deficiency and dysregulation (PIDD) disorders associated with autoimmune complications, but the full immunological spectrum of RTS2 remains incompletely understood. The French OBS’CEREVANCE cohort has included all consecutive cases of paediatric-onset autoimmune cytopenia from participating centres since 2004 and provides prospective, long-term observational follow-up. Leveraging this unbiased national database, which includes 406 patients with paediatric-onset Evans syndrome (pES) with a median follow-up of 9 years, we identified three children with pES and RTS2. Results All patients exhibited typical clinical features of RTS2 and carried heterozygous pathogenic variants in EP300 (two de novo stop-gain variants, c.1942C > T and c.4933C > T, and one missense variant in the catalytic domain, c.4351C > T). Severe autoimmune cytopenias were diagnosed at 4, 5, and 7 years of age and required prolonged immunomodulatory therapies. Two patients had non-malignant lymphoproliferation, including one with granulomatous-lymphocytic interstitial lung disease. Immunological evaluations revealed variable humoral and cellular abnormalities, including hypogammaglobulinemia; deficiencies in naïve CD4 T cells, naïve CD8 T cells, and switched memory B cells; and a positive interferon signature. Comprehensive genetic investigations excluded alternative monogenic causes of PIDD. Genome-wide DNA methylation profiling demonstrated that all three patients with pES clustered with reference EP300 pathogenic variant carriers, confirming the presence of the robust EP300 episignature, without a distinct secondary DNA methylation signature specifically differentiating the pES phenotype. Longitudinal blood samples showed stable epigenetic profiles over time. Conclusions This study expands the phenotypic spectrum of EP300 -related RTS by identifying pES as a severe manifestation of immune dysregulation associated with this chromatinopathy. Although these patients display the canonical EP300 DNA methylation episignature, the absence of a distinct secondary methylation profile suggests complex, multifactorial contributions to autoimmunity. Clinicians should be aware of this rare association, to ensure prompt immunological evaluation and follow-up in patients with EP300 -related RTS and prompt genetic evaluation of paediatric or adult patients with ES by haemato-immunologists.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11515893/v1
Primary Topic
Immunodeficiency and Autoimmune Disorders
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Expanding the phenotype of EP300-related Rubinstein-Taybi syndrome: Evans syndrome and DNA methylation profiling in three individuals

Camille Charbonnier, Bénédicte Neven, Patricia Fergelot, Églantine Hullo et al.
Research Square
Immunodeficiency and Autoimmune Disorders
preprint

Expanding the phenotype of EP300-related Rubinstein-Taybi syndrome: Evans syndrome and DNA methylation profiling in three individuals

Camille Charbonnier, Bénédicte Neven, Patricia Fergelot, Églantine Hullo, Nathalie Aladjidi, Agathe Escudier, Anne Pagnier, Julien Thévenon, Maria Merched, Nour El Housseini, Sébastien Heritier, Anne‐Claire Richard, Gaël Nicolas, Didier Lacombe, Thibaut César, Mony Fahd, Coralie Briand, Amandine Santini, Julien Gils
preprint en

Abstract

Abstract Background Rubinstein-Taybi syndrome type 2 (RTS2) is a rare chromatinopathy caused by pathogenic variants in EP300 and is characterised by developmental delay, distinctive facial dysmorphic features, and broad extremities. Chromatinopathies are increasingly recognised as syndromic primary immune deficiency and dysregulation (PIDD) disorders associated with autoimmune complications, but the full immunological spectrum of RTS2 remains incompletely understood. The French OBS’CEREVANCE cohort has included all consecutive cases of paediatric-onset autoimmune cytopenia from participating centres since 2004 and provides prospective, long-term observational follow-up. Leveraging this unbiased national database, which includes 406 patients with paediatric-onset Evans syndrome (pES) with a median follow-up of 9 years, we identified three children with pES and RTS2. Results All patients exhibited typical clinical features of RTS2 and carried heterozygous pathogenic variants in EP300 (two de novo stop-gain variants, c.1942C > T and c.4933C > T, and one missense variant in the catalytic domain, c.4351C > T). Severe autoimmune cytopenias were diagnosed at 4, 5, and 7 years of age and required prolonged immunomodulatory therapies. Two patients had non-malignant lymphoproliferation, including one with granulomatous-lymphocytic interstitial lung disease. Immunological evaluations revealed variable humoral and cellular abnormalities, including hypogammaglobulinemia; deficiencies in naïve CD4 T cells, naïve CD8 T cells, and switched memory B cells; and a positive interferon signature. Comprehensive genetic investigations excluded alternative monogenic causes of PIDD. Genome-wide DNA methylation profiling demonstrated that all three patients with pES clustered with reference EP300 pathogenic variant carriers, confirming the presence of the robust EP300 episignature, without a distinct secondary DNA methylation signature specifically differentiating the pES phenotype. Longitudinal blood samples showed stable epigenetic profiles over time. Conclusions This study expands the phenotypic spectrum of EP300 -related RTS by identifying pES as a severe manifestation of immune dysregulation associated with this chromatinopathy. Although these patients display the canonical EP300 DNA methylation episignature, the absence of a distinct secondary methylation profile suggests complex, multifactorial contributions to autoimmunity. Clinicians should be aware of this rare association, to ensure prompt immunological evaluation and follow-up in patients with EP300 -related RTS and prompt genetic evaluation of paediatric or adult patients with ES by haemato-immunologists.

Research Square
Université de Bordeaux (FR), Université Paris Cité (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Hôpital Armand-Trousseau (FR), Hôpital Robert-Debré (FR), Hôpital Jean-Verdier (FR), Université de Rouen Normandie (FR), Université Grenoble Alpes (FR)
Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale
Good health and well-being
Immunodeficiency and Autoimmune Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon